Compare Amgen, Inc. (AMGN) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Indonesia Energy Corporation Limited — how do they compare? Amgen, Inc. trades at $361.92 (market cap $196.12B), while Indonesia Energy Corporation Limited trades at $2.83 (market cap $42.16M). The key difference: Amgen, Inc. is far larger — about 4651.8× Indonesia Energy Corporation Limited's market cap, and Amgen, Inc. pays a 2.77% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| AMGN | INDO | |
|---|---|---|
Market Cap | $196.12B | $42.16M |
Sector | Health | Energy |
52-Week High | $388.16 | $6.74 |
52-Week Low | $271.18 | $2.49 |
Enterprise Value | $241.41B | $37.53M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
INDO trades at $2.74, down 0.72% today, with a neutral technical signal. The company shows negative profitability with a net income margin of -253.4% and a P/S ratio of 19.96, indicating high valuation relative to sales. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block, which could drive future revenue growth. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of new well operations to improve financials. Risks include persistent losses and oil market volatility. Upside potential exists if production targets are met, but investors should weigh high operational risks against speculative growth prospects in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
